RNA carriers are important in overcoming the physiological barriers of systemic administration of RNA-based drugs. However, they provide a challenge in the translation of RNA medicines to the clinical setting. After the recent success of the lipid nanoparticle-based mRNA vaccines against COVID-19, lipid carriers have become the primary RNA delivery vehicle. However, since lipid nanoparticles can be toxic to cells and stimulate the release of systemic inflammatory cytokines, interest in natural transporters such as exosomes is gaining momentum. Other nontoxic and nonimmunogenic carriers such as structurally and functionally peptides are also attracting attention. Novel technologies including carbon nanotubes and other inorganic biocompatible polymers, carbon nanodots, and functionalized or hybrid systems are also exciting avenues of exploration and evaluation.